ECElias B. Chahine

Elias B. Chahine

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elias B. Chahine has a total of 232 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Bictegravir/Lenacapavir: A 2-Drug Regimen for the Treatment of HIV-1 Infection

    by Elias B. Chahine, John J. Faragon, Nimish Patel, Elizabeth M. Sherman

    Objective: To evaluate the efficacy and safety of bictegravir/lenacapavir for the treatment of HIV-1 infection. Data Sources: A literature search was conducted in PubMed and Google Scholar (January 2016-August 2026) using the search terms bictegravir and lenacapavir . Other data sources included abstracts presented at recent conferences and the prescribing information. Study Selection and Data Extraction: All English-language studies assessing the efficacy and safety of bictegravir/lenacapavir for the treatment of HIV-1 infection were considered for inclusion. Data Synthesis: Bictegravir is an established second-generation integrase strand transfer inhibitor (INSTI), whereas lenacapavir is a novel capsid inhibitor. Both antiretrovirals are highly active against HIV-1. Bictegravir/lenacapavir 75 mg/50 mg was shown to be safe and effective in two phase 3 clinical trials after switching from complex antiretroviral therapy (ART) or bictegravir/emtricitabine/tenofovir alafenamide. The Food and Drug Administration approved this combination for the treatment of HIV-1 infection in adults who are virologically suppressed on stable ART with no resistance to the individual components. It is available as a single-tablet regimen (STR) taken orally once daily. Relevance to Patient Care and Clinical Practice in Comparison With Existing Drugs: Bictegravir/lenacapvir is the first INSTI-capsid inhibitor 2-drug STR indicated for the treatment of HIV-1 infection. The combination could be useful for patients who want to simplify their regimen and/or those who cannot use a nucleos(t)ide or a non-nucleoside reverse transcriptase inhibitor. It is not active against hepatitis B virus coinfection. Conclusions: Bictegravir/lenacapvir is safe and efficacious as a 2-drug regimen for the treatment of adults with HIV-1 infection.

  • Doravirine/Islatravir: A 2-Drug Regimen for the Treatment of HIV-1 Infection

    by Elias B. Chahine, David E. Koren, Rafik Samuel, Harrison Van der Kloot, Elizabeth M. Sherman

    Objective: The objective of this study is to review the efficacy and safety of doravirine/islatravir for the treatment of HIV-1 infection. Data Sources: A literature search was conducted in PubMed and Google Scholar (January 2016–June 2026) using the search terms doravirine or MK-1439 and islatravir or MK-8591 . Other resources included abstracts presented at recent conferences and the prescribing information. Study Selection and Data Extraction: All English-language studies assessing the efficacy and safety of doravirine/islatravir for the treatment of HIV-1 infection were included. Data Synthesis: Doravirine is an established second-generation nonnucleoside reverse transcriptase inhibitor. Islatravir is a new nucleoside reverse transcriptase inhibitor that uniquely interferes with translocation and is highly active against HIV-1. Doravirine/islatravir once daily was shown to be safe and effective in three phase 3 clinical trials, using a lower dose of islatravir (0.25 mg), after a higher dose (0.75 mg) was shown in earlier trials to reduce total lymphocyte and CD4+ T-cell counts. The FDA approved this combination for the treatment of HIV-1 infection in adults who are virologically suppressed on stable antiretroviral therapy with no history of virologic treatment failure and no known resistance to doravirine. Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs: Doravirine/islatravir is the first integrase strand transfer inhibitor-free 2-drug regimen indicated for the treatment of HIV-1 infection. The combination could be useful for patients who want to simplify their regimen and those who cannot receive an integrase inhibitor. Conclusions: Doravirine/islatravir is safe and effective as a 2-drug regimen for the treatment of HIV-1 infection.

  • Open Access

    Importance of Residency Training for the Provision of Comprehensive Clinical Pharmacy Services

    by Keith M. Olsen, Jill S. Borchert, P. Brandon Bookstaver, Elias B. Chahine, Kathryn A. Connor, Aaron M. Cook, Meghan Dye, Ryan Dull, W. Anthony Hawkins, Kathleen K. Adams, et al.

    In 2006, the American College of Clinical Pharmacy (ACCP) issued a position statement recommending residency training as a prerequisite for entering direct patient care activities. Additional recommendations in 2013 added residency training as a prerequisite for providing direct patient care. Over the subsequent 12 years, patient‐level services by pharmacists expanded, and the frequency of team‐based care increased. The Educational Affairs Committee acknowledges these changes in education and clinical pharmacy practice and asserts that postgraduate year one (PGY1) residency training remains a prerequisite to prepare a pharmacist to provide comprehensive clinical pharmacy services. A postgraduate year two (PGY2) residency in specialty care is recommended for the provision of specialty care, recognizing the current system lacks the capacity to provide training for all. The 2025 committee adds the recommendation that completion of residency training is also necessary for the advancement of indirect patient care skills, and all programs should be accredited through standards‐based review. When residency training is not available, the committee recommends resident equivalency be achieved through professional development. The complexities of medication management necessitate residency training; therefore, the pharmacy profession needs to actively expand training programs and establish standards for alternative training models.


  • Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea

    by Spencer H. Durham, Amanda K. McAllister, Elias B. Chahine

    Objective: To review the efficacy and safety of gepotidacin for the treatment of uncomplicated urogenital gonorrhea (uUGG). Data Sources: A literature search of PubMed and Google Scholar (January 2010 to January 2026) was conducted using the terms gepotidacin and GSK2140944. Additional sources included conference abstracts, the manufacturer’s website, and prescribing information. Study Selection and Data Extraction: Relevant English-language studies evaluating the efficacy and safety of gepotidacin for uUGG were included. Data Synthesis: Gepotidacin is a first-in-class triazaacenaphthylene antibiotic with a novel mechanism of action and potent activity against Neisseria gonorrhoeae . In the phase 3 EAGLE-1 trial, gepotidacin demonstrated noninferiority to ceftriaxone plus azithromycin for uUGG treatment. It was generally well tolerated, with gastrointestinal adverse effects most commonly reported. Gepotidacin is administered as 3000 mg orally every 12 hours for 2 doses and is approved for adults and pediatric patients aged ≥12 years weighing ≥45 kg with limited or no alternative treatment options. Administration with food is recommended to reduce gastrointestinal adverse effects. Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs: Gepotidacin provides a new 2-dose oral option for uUGG treatment. Compared with ceftriaxone, the current drug of choice, oral administration may improve convenience and access. Similar to cefixime and zoliflodacin, its oral formulation may facilitate treatment while potentially reducing microbiome disruption compared with ceftriaxone. Conclusions: Gepotidacin is a promising oral antibiotic with a novel mechanism of action and demonstrated efficacy for uUGG treatment.


  • Lenacapavir: A Twice-Yearly Injectable for HIV Preexposure Prophylaxis

    by David E. Koren, Elias B. Chahine, Elizabeth M. Sherman

    Objective: To review the efficacy and safety of lenacapavir for the prevention of HIV-1 infection. Data Sources: Clinical trials and review articles were obtained through August 2025 using search terms lenacapavir, GS-CA1, GS-6207, capsid inhibitor, preexposure prophylaxis, and PrEP. Study Selection and Data Extraction: All relevant articles, trials, and abstracts in the English language were included. Data Synthesis: Lenacapavir uses a novel mechanism for HIV prevention administered through subcutaneous injection. In a counterfactual design, lenacapavir arms demonstrated superior efficacy for prevention against a background HIV incidence rate across a variety of populations and gender identities. Adverse events commonly reported include injection-site reactions, which may include nodules, pain, or swelling at the injection site. Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs: The extended dosing frequency of lenacapavir may uniquely serve patients at risk of HIV acquisition who are unable or unwilling to take oral prevention medications. The mechanism of action for lenacapavir is not duplicative of other medications used in first-line antiretroviral regimens and thus may not risk resistance to regularly used classes if resistance occurs. Lenacapavir is a moderate cytochrome P450 inhibitor and thus may have interactions with other medications; however, neither renal nor hepatic dose adjustments are required. Conclusions: Lenacapavir provides a long-acting injectable option for people seeking a pharmacologic prevention agent against HIV-1. Despite injection-site reactions being relatively common, these did not present a barrier to treatment continuation among trial participants.


  • Prematriculation Programs for Student Pharmacist Success

    by Zara Risoldi Cochrane, Oluwaranti (Ranti) Akiyode, Evan T. Robinson, Elias B. Chahine, Duc P. Do, Molly G. Minze


  • Open Access

    Exploration of Psychosocial Hazards: Core Values, Justice and Fairness, and Social Support to Address Workforce Well-Being

    by Seena L. Haines, Kelly C. Lee, Kelly N. Gable, Jonathan Thigpen, Caitlin M. Gibson, Susan Morley, Ashley N. Crowl, Elias B. Chahine, Michelle L. Hilaire, Kathy E. Komperda, et al.


  • Gepotidacin: A Novel Antibiotic for the Treatment of Uncomplicated Urinary Tract Infections

    by Spencer H. Durham, Elias B. Chahine

    Objective: To review the efficacy and safety of gepotidacin for the treatment of uncomplicated urinary tract infections (uUTIs). Data Sources: A literature search was performed using PubMed and Google Scholar (both January 2010 to March 2025) with the search terms gepotidacin and GSK2140944. Other resources included conference abstracts, the manufacturer’s web site, and prescribing information. Study Selection and Data Extraction: All relevant English-language studies assessing gepotidacin efficacy and safety for the treatment of uUTIs were included. Data Synthesis: Gepotidacin is a first-in-class triazaacenaphthylene antibiotic with a novel mechanism of action that is active against strains of Escherichia coli resistant to other classes of antibiotics, including the fluoroquinolones. Gepotidacin was non-inferior to nitrofurantoin in the treatment of healthy, non-pregnant females aged 12 years and older with uUTIs. Gastrointestinal effects are the most common adverse effects, and it has several potential drug-drug interactions. Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs Gepotidacin has been directly compared to nitrofurantoin for the treatment of uUTIs, but not to other commonly used drugs, such as trimethoprim/sulfamethoxazole, fosfomycin, beta-lactams, and fluoroquinolones. However, it may be active against organisms resistant to these traditionally used agents due to its novel mechanism of action, making it an attractive option for patients with UTIs due to multidrug-resistant organisms. It should be administered with food to help decrease gastrointestinal-related adverse effects. Conclusions: Gepotidacin is an antibiotic with a novel mechanism of action that is efficacious in the treatment of women with uUTIs caused by common uropathogens, including resistant strains.


  • Top Cited Papers
    Open Access

    Guidelines for the Prevention, Diagnosis, and Management of Urinary Tract Infections in Pediatrics and Adults

    by Zachary Nelson, Abdullah Tarık Aslan, Nathan P. Beahm, Michelle Blyth, Matthew Cappiello, Danielle Casaus, Fernando Dominguez, Susan Egbert, Alexandra Hanretty, Tina Khadem, et al.

    Importance: Traditional approaches to practice guidelines frequently result in dissociation between strength of recommendation and quality of evidence. Objective: To create a clinical guideline for the diagnosis and management of urinary tract infections that addresses the gap between the evidence and recommendation strength. Evidence Review: This consensus statement and systematic review applied an approach previously established by the WikiGuidelines Group to construct collaborative clinical guidelines. In May 2023, new and existing members were solicited for questions on urinary tract infection prevention, diagnosis, and management. For each topic, literature searches were conducted up until early 2024 in any language. Evidence was reported according to the WikiGuidelines charter: clear recommendations were established only when reproducible, prospective, controlled studies provided hypothesis-confirming evidence. In the absence of such data, clinical reviews were developed discussing the available literature and associated risks and benefits of various approaches. Findings: A total of 54 members representing 12 countries reviewed 914 articles and submitted information relevant to 5 sections: prophylaxis and prevention (7 questions), diagnosis and diagnostic stewardship (7 questions), empirical treatment (3 questions), definitive treatment and antimicrobial stewardship (10 questions), and special populations and genitourinary syndromes (10 questions). Of 37 unique questions, a clear recommendation could be provided for 6 questions. In 3 of the remaining questions, a clear recommendation could only be provided for certain aspects of the question. Clinical reviews were generated for the remaining questions and aspects of questions not meeting criteria for a clear recommendation. Conclusions and Relevance: In this consensus statement that applied the WikiGuidelines method for clinical guideline development, the majority of topics relating to prevention, diagnosis, and treatment of urinary tract infections lack high-quality prospective data and clear recommendations could not be made. Randomized clinical trials are underway to address some of these gaps; however further research is of utmost importance to inform true evidence-based, rather than eminence-based practice.


  • Open Access

    Let's Have a Chat: How Well Does an Artificial Intelligence Chatbot Answer Clinical Infectious Diseases Pharmacotherapy Questions?

    by Wesley D Kufel, Kathleen D Hanrahan, Robert W Seabury, Katie A Parsels, Jason C Gallagher, Conan MacDougall, Elizabeth W Covington, Elias B Chahine, Rachel S Britt, Jeffrey M Steele

    Background: It is unknown whether ChatGPT provides quality responses to infectious diseases (ID) pharmacotherapy questions. This study surveyed ID pharmacist subject matter experts (SMEs) to assess the quality of ChatGPT version 3.5 (GPT-3.5) responses. Methods: The primary outcome was the percentage of GPT-3.5 responses considered useful by SME rating. Secondary outcomes were SMEs' ratings of correctness, completeness, and safety. Rating definitions were based on literature review. One hundred ID pharmacotherapy questions were entered into GPT-3.5 without custom instructions or additional prompts, and responses were recorded. A 0–10 rating scale for correctness, completeness, and safety was developed and validated for interrater reliability. Continuous and categorical variables were assessed for interrater reliability via average measures intraclass correlation coefficient and Fleiss multirater kappa, respectively. SMEs' responses were compared by the Kruskal-Wallis test and chi-square test for continuous and categorical variables. Results: SMEs considered 41.8% of responses useful. Median (IQR) ratings for correctness, completeness, and safety were 7 (4–9), 5 (3–8), and 8 (4–10), respectively. The Fleiss multirater kappa for usefulness was 0.379 (95% CI, .317–.441) indicating fair agreement, and intraclass correlation coefficients were 0.820 (95% CI, .758–.870), 0.745 (95% CI, .656–.816), and 0.833 (95% CI, .775–.880) for correctness, completeness, and safety, indicating at least substantial agreement. No significant difference was observed among SME responses for percentage of responses considered useful. Conclusions: Fewer than 50% of GPT-3.5 responses were considered useful by SMEs. Responses were mostly considered correct and safe but were often incomplete, suggesting that GPT-3.5 responses may not replace an ID pharmacist's responses.